Company Filing History:
Years Active: 2012-2013
Title: Mike Grimwood: Innovator in Calcium Channel Blocker Technologies
Introduction
Mike Grimwood is a distinguished inventor based in North Vancouver, Canada, with a notable track record in the field of pharmaceutical innovations. He holds three patents that contribute significantly to medical science, particularly in the area of calcium channel blockers. His expertise in developing novel compounds has paved the way for advancements in treatment methods for conditions related to calcium channel activity.
Latest Patents
Among his latest inventions, Mike Grimwood has patented a series of N-piperidinyl acetamide derivatives designed as calcium channel blockers. These methods and compounds are effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly targeting T-type calcium channels. The detailed formulation of these compounds is outlined in his patented work, contributing to the ongoing development of innovative therapeutic solutions.
Career Highlights
Mike Grimwood is currently affiliated with Zalicus Pharmaceuticals, Ltd., where he continues to innovate in the pharmaceutical sector. His work has been integral to the company's mission of pioneering cutting-edge treatments for a variety of health conditions, showcasing his commitment to advancing medical science through patentable inventions.
Collaborations
Throughout his career, Mike Grimwood has collaborated with notable colleagues such as Hassan Pajouhesh and Yanbing Ding. These partnerships have been instrumental in driving research efforts forward, combining their expertise to enhance the quality and impact of their innovative projects.
Conclusion
In conclusion, Mike Grimwood stands out as a dedicated inventor whose contributions to calcium channel blocker technologies signify a promising direction in pharmaceutical research. With his trio of patents, he exemplifies the spirit of innovation that drives the medical community towards better treatment options and improved patient outcomes.